IN2012DN02711A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02711A IN2012DN02711A IN2711DEN2012A IN2012DN02711A IN 2012DN02711 A IN2012DN02711 A IN 2012DN02711A IN 2711DEN2012 A IN2711DEN2012 A IN 2711DEN2012A IN 2012DN02711 A IN2012DN02711 A IN 2012DN02711A
- Authority
- IN
- India
- Prior art keywords
- glucose
- animal
- amg
- gastrointestinal
- sglt
- Prior art date
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 4
- 230000002496 gastric effect Effects 0.000 abstract 4
- 239000008103 glucose Substances 0.000 abstract 4
- HOVAGTYPODGVJG-ZFYZTMLRSA-N methyl alpha-D-glucopyranoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HOVAGTYPODGVJG-ZFYZTMLRSA-N 0.000 abstract 3
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000029142 excretion Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 abstract 1
- 108091052347 Glucose transporter family Proteins 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229940121377 sodium-glucose co-transporter inhibitor Drugs 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Pathology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24257009P | 2009-09-15 | 2009-09-15 | |
| PCT/US2010/048752 WO2011034846A1 (en) | 2009-09-15 | 2010-09-14 | Use of alpha-methylglucoside (amg) as an indicator for glucose absorption and excretion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02711A true IN2012DN02711A (enExample) | 2015-09-11 |
Family
ID=42983318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2711DEN2012 IN2012DN02711A (enExample) | 2009-09-15 | 2010-09-14 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8147801B2 (enExample) |
| EP (1) | EP2478357A1 (enExample) |
| JP (1) | JP5722901B2 (enExample) |
| CN (1) | CN102597770B (enExample) |
| AU (1) | AU2010295722B2 (enExample) |
| IN (1) | IN2012DN02711A (enExample) |
| WO (1) | WO2011034846A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12115232B2 (en) * | 2017-11-21 | 2024-10-15 | Solvex Limited Liability Company | Preparation for magnetic resonance diagnostics for oncological diseases, comprising deuterated 3-O-methylglucose, and diagnostic method using said preparation |
| JP7570663B2 (ja) | 2020-07-22 | 2024-10-22 | 国立大学法人群馬大学 | 糖尿病、肥満および／または脂肪肝に対する新規診断マーカーおよび新規治療用組成物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100351263C (zh) * | 2002-08-08 | 2007-11-28 | 橘生药品工业株式会社 | 吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体 |
| DE60332743D1 (de) * | 2002-08-08 | 2010-07-08 | Kissei Pharmaceutical | Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung |
| JP2005015460A (ja) * | 2002-10-29 | 2005-01-20 | Takeda Chem Ind Ltd | Ｓｇｌｔホモログ用途 |
| AU2003275713A1 (en) | 2002-10-29 | 2004-05-25 | Takeda Pharmaceutical Company Limited | Use of sglt homolog |
| EP1601795A4 (en) * | 2003-03-07 | 2008-03-26 | Threshold Pharmaceuticals Inc | METHOD FOR DETERMINING THE SENSITIVITY OF A TUMOR AGAINST TREATMENT WITH AN ANTI-TUMBER AGENT |
| ES2649737T5 (es) | 2003-08-01 | 2021-07-07 | Mitsubishi Tanabe Pharma Corp | Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio |
| EA010655B1 (ru) | 2003-08-01 | 2008-10-30 | Янссен Фармацевтика Н.В. | Замещенные индазол-о-глюкозиды |
| JP2005139093A (ja) * | 2003-11-05 | 2005-06-02 | Nichirei Corp | グルコース吸収阻害剤およびその製造方法 |
| AR053329A1 (es) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt) |
| TWI418556B (zh) | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | 吲哚衍生物 |
| TW200904454A (en) | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof |
| JP2009155212A (ja) * | 2007-12-25 | 2009-07-16 | Taisho Pharmaceutical Co Ltd | Ｃ−フェニル１−チオグルシト−ル化合物を有効成分とする糖尿病治療剤 |
-
2010
- 2010-09-14 IN IN2711DEN2012 patent/IN2012DN02711A/en unknown
- 2010-09-14 WO PCT/US2010/048752 patent/WO2011034846A1/en not_active Ceased
- 2010-09-14 AU AU2010295722A patent/AU2010295722B2/en not_active Ceased
- 2010-09-14 EP EP10755292A patent/EP2478357A1/en not_active Withdrawn
- 2010-09-14 US US12/881,695 patent/US8147801B2/en not_active Expired - Fee Related
- 2010-09-14 CN CN201080051671.0A patent/CN102597770B/zh not_active Expired - Fee Related
- 2010-09-14 JP JP2012529847A patent/JP5722901B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011034846A1 (en) | 2011-03-24 |
| CN102597770B (zh) | 2016-08-10 |
| AU2010295722B2 (en) | 2015-04-16 |
| US20110065200A1 (en) | 2011-03-17 |
| JP2013504769A (ja) | 2013-02-07 |
| CN102597770A (zh) | 2012-07-18 |
| US8147801B2 (en) | 2012-04-03 |
| JP5722901B2 (ja) | 2015-05-27 |
| AU2010295722A1 (en) | 2012-04-12 |
| EP2478357A1 (en) | 2012-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013010952A2 (pt) | sistemas de rmn e métodos para a detecção rápida de analisados | |
| GB2459228A (en) | Exosome-associated microrna as a diagnostic marker | |
| EP4335932A3 (en) | Methods of monitoring conditions by sequence analysis | |
| WO2011015602A3 (en) | Lung cancer biomarkers | |
| WO2009085234A3 (en) | Use of micro-rna as a biomarker of immunomodulatory drug activity | |
| WO2009025852A3 (en) | Methods of using mirna for detection of in vivo cell death | |
| MX361731B (es) | Método para diagnosticar cáncer y kit de diagnóstico usando medición de actividad de células nk. | |
| MX2008014679A (es) | Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry. | |
| ES2570632T3 (es) | Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal | |
| MX2010014228A (es) | Metodos y productos de diagnostico del p/gf-1 acompañante. | |
| ATE512681T1 (de) | Dialysesystem mit nichtinvasiver temperaturmessung | |
| MX2013000916A (es) | Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales. | |
| WO2008057437A3 (en) | Ex vivo flow cytometry method and device | |
| WO2008021290A9 (en) | Organ-specific proteins and methods of their use | |
| EP2209495A4 (en) | TAZ / WWTR1 FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| FR2944019B1 (fr) | Procede de dosage de la prodefensine-a6 pour le diagnostic in vitro du cancer colorectal. | |
| FR2919060B1 (fr) | Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal. | |
| EP2585826A4 (en) | METHODS AND COMPOSITIONS FOR DIAGNOSING AND PROGNOSING RENAL INJURY AND RENAL FAILURE | |
| GB0711327D0 (en) | Diagnostic method | |
| WO2010028373A3 (en) | Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients | |
| WO2010033773A3 (en) | Diagnostic, prognostic and therapeutic uses of mirs in adaptive pathways and/or disease pathways | |
| WO2012006056A3 (en) | Ccr6 as a biomarker of alzheimer's disease | |
| BR112014009223A8 (pt) | método para o diagnóstico da doença de niemann-pick | |
| FR2904450B1 (fr) | Systeme de simulation de capteur. | |
| IN2012DN02711A (enExample) |